



Henan Province include IPF into its "Important, Special, and Major Disease Outpatient Insurance"

March 6, 2018 - Henan Province announced expansion of its insurance coverage of drugs used for outpatients of Special, Important, and Major Diseases. Idiopathic pulmonary fibrosis (IPF) is included in the coverage for therapies of the newly added 16 diseases.

In China, after Central Government included Pirfenidone/Etuary® for IPF therapy in insurance coverage, each province is authorized to set up their own insurance policy, including how much to be paid and what kind of patients can be paid. Previously in Henan Province, the annual insurance coverage was limited to 80% reimbursement for inpatients up to 100,000RMB and only 200RMB reimbursement for outpatients. Current expansion of coverage will include outpatients also at 80% reimbursement, which will benefit the majority of IPF patients. Henan Province has a population of nearly 100 million. Current policy will start to be in effect on April 1, 2018.

About GNI Group Ltd.

GNI Group Ltd. is a multinational life science company listed on the Tokyo Stock Exchange Mothers Market, Code 2160. The Group is headquartered in Tokyo, with primary business units of pharmaceuticals and medical devices with subsidiaries in Hong Kong, Shanghai, Beijing and the United States. For further information about GNI Group Ltd., please visit www.gnipharma.com.

For further inquiries

+81 (03) 6214-3600

Email: infojapan@gnipharma.com

This press release contains "forward-looking" statements, including statements related to the Group's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "expected to", "will" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause the Group's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. The Group does not undertake any obligation to update forward-looking statements.